|
1
|
Xu BY, Jin K, Wu HS, Liu XJ, Wang XJ, Sang H, Li KQ, Sun MJ, Meng HQ, Deng HL, Xun ZY, Yang XD, Zhang L, Li GJ, Zhang RL, Cai DF, Liu JH, Zhao GJ, Liu LF, Wang G, Zhao CL, Guo B, Jin SC, Huang LY, Yang FD, Zheng JM, Zhan GL, Fang MS, Meng XJ, Zhang GY, Li HM, Liu XL, Li JH, Wu B, Li HY, Chen JD. Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia. World J Psychiatry 2024; 14:1735-1745. [PMID: 39564169 PMCID: PMC11572666 DOI: 10.5498/wjp.v14.i11.1735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2024] [Revised: 10/14/2024] [Accepted: 10/29/2024] [Indexed: 11/07/2024] Open
Abstract
BACKGROUND Blonanserin (BNS) is a well-tolerated and effective drug for treating schizophrenia. AIM To investigate which types of patients would obtain the most benefit from BNS treatment. METHODS A total of 3306 participants were evaluated in a 12-week, prospective, multicenter, open-label post-marketing surveillance study of BNS. Brief psychiatric rating scale (BPRS) scores were calculated to evaluate the effectiveness of BNS, and its safety was assessed with the incidence of adverse drug reactions. Linear regression was used to screen the influencing factors for the reduction of BPRS total score, and logistic regression was used to identify patients with a better response to BNS. RESULTS The baseline BPRS total score (48.8 ± 15.03) decreased to 27.7 ± 10.08 at 12 weeks (P < 0.001). Extrapyramidal symptoms (14.6%) were found to be the most frequent adverse drug reactions. The acute phase, baseline BPRS total score, current episode duration, number of previous episodes, dose of concomitant antipsychotics, and number of types of sedative-hypnotic agents were found to be independent factors affecting the reduction of BPRS total score after treatment initiation. Specifically, patients in the acute phase with baseline BPRS total score ≥ 45, current episode duration < 3 months, and ≤ 3 previous episodes derived greater benefit from 12-week treatment with BNS. CONCLUSION Patients in the acute phase with more severe symptoms, shorter current episode duration, fewer previous episodes, and a lower psychotropic drug load derived the greatest benefit from treatment with BNS.
Collapse
Affiliation(s)
- Bao-Yan Xu
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China
- Department of Psychiatry, Hebei Provincial Mental Health Center, Hebei Key Laboratory of Major Mental and Behavioral Disorders, The Sixth Clinical Medical College of Hebei University, Baoding 071000, Hebei Province, China
| | - Kun Jin
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China
| | - Hai-Shan Wu
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China
| | - Xue-Jun Liu
- Department of Psychiatry, Brain Hospital of Hunan Province, Changsha 410000, Hunan Province, China
| | - Xi-Jin Wang
- Department of Psychiatry, The First Psychiatric Hospital of Harbin, Harbin 150000, Heilongjiang Province, China
| | - Hong Sang
- Mental Health Center, Changchun Sixth Hospital, Changchun 130000, Jilin Province, China
| | - Ke-Qing Li
- Department of Psychiatry, Hebei Provincial Mental Health Center, Hebei Key Laboratory of Major Mental and Behavioral Disorders, The Sixth Clinical Medical College of Hebei University, Baoding 071000, Hebei Province, China
| | - Mei-Juan Sun
- Department of Pharmacy, Daqing Third Hospital, Daqing 163000, Heilongjiang Province, China
| | - Hua-Qing Meng
- Department of Physical and Psychological Rehabilitation, Guangda Rehabilitation Hospital, Chongqing 400000, China
| | - Huai-Li Deng
- Department of Psychology, Shanxi Provincial Mental Health Center, Taiyuan 030000, Shanxi Province, China
| | - Zhi-Yuan Xun
- Department of Psychiatry, Tianjin Anding Hospital, Tianjin 300000, China
| | - Xiao-Dong Yang
- Department of Psychiatry, Shandong Mental Health Center, Jinan 250000, Shandong Province, China
| | - Lin Zhang
- Department of Psychiatry, Fuzhou Shenkang Hospital, Fuzhou 350000, Fujian Province, China
| | - Guan-Jun Li
- Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200000, China
| | - Rui-Ling Zhang
- Department of Psychiatry, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan Province, China
| | - Duan-Fang Cai
- Department of Psychiatry, The Fifth People’s Hospital of Zigong, Zigong 643000, Sichuan Province, China
| | - Jia-Hong Liu
- Department of Psychiatry, The Affiliated Kangning Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
| | - Gui-Jun Zhao
- Department of Psychiatry, Guangyuan Mental Health Center, Guangyuan 628000, Sichuan Province, China
| | - Long-Fa Liu
- Department of Psychiatry, Jilin Sixth People’s Hospital, Jilin 132000, Jilin Province, China
| | - Gang Wang
- The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100000, China
- Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100000, China
| | - Chang-Lie Zhao
- Department of Psychiatry, Yanbian Brain Hospital, Yanbian 133000, Jilin Province, China
| | - Bin Guo
- Department of Psychiatry, Mudanjiang Psychiatric Hospital, Mudanjiang 157000, Heilongjiang Province, China
| | - Sheng-Chun Jin
- Department of Psychiatry, Anhui Mental Health Center, Hefei 230000, Anhui Province, China
| | - Ling-Yun Huang
- Mental Health Center, Yueqing Third People’s Hospital, Yueqing 325600, Zhejiang Province, China
| | - Fu-De Yang
- Psychiatry Research Center, Beijing Huilongguan Hospital, Beijing 100000, China
| | - Jian-Min Zheng
- Department of Mental Health, Fuzhou Taijiang Xinshengkang Psychiatric Clinic, Fuzhou 350000, Fujian Province, China
| | - Gui-Lai Zhan
- Department of Psychiatry, Xuhui Mental Health Center, Shanghai 200000, China
| | - Mao-Sheng Fang
- Department of Psychiatry, Affiliated Wuhan Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China
| | - Xiang-Jun Meng
- Dean’s Office, Qingdao Mental Health Center, Qingdao 266000, Shandong Province, China
| | - Guang-Ya Zhang
- Department of Psychiatry, Suzhou Guangji Hospital, Affiliated Guangji Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China
| | - Hai-Min Li
- Department of Psychiatry, Chengdu Qingyang Aaron Clinic, Chengdu 610000, Sichuan Province, China
| | - Xiang-Lai Liu
- Institute of Mental Health, Hainan Provincial Anning Hospital, Haikou 570000, Hainan Province, China
| | - Ju-Hong Li
- Department of Psychiatry, The Fourth People’s Hospital of Chengdu, Chengdu 610000, Sichuan Province, China
| | - Bin Wu
- Department of Psychiatry, Xi’an Mental Health Center, Xi’an 710000, Shaanxi Province, China
| | - Hai-Yun Li
- Medical Affairs, Sumitomo Pharma (Suzhou) Co., Ltd., Shanghai 200000, China
| | - Jin-Dong Chen
- Department of Psychiatry, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China
| |
Collapse
|
|
3
|
Woo YS, Yoon BH, Jeon BH, Seo JS, Nam B, Lee SY, Jae YM, Jang SH, Eun HJ, Won SH, Lee K, Lee J, Bahk WM. Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE 2019; 17:423-431. [PMID: 31352709 PMCID: PMC6705098 DOI: 10.9758/cpn.2019.17.3.423] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 10/25/2018] [Accepted: 10/26/2018] [Indexed: 12/26/2022]
Abstract
Objective This study was performed to investigate the efficacy and tolerability of blonanserin in schizophrenic patients who were previously treated with other antipsychotics but, due to insufficient response, were switched to blonanserin. Methods A total of 52 patients with schizophrenia who were unresponsive to treatment with antipsychotic monotherapy or combination therapy were recruited into this 12-week, open-label, prospective, multicenter study. Patients were switched to blonanserin from their existing antipsychotics over a maximum 2-week tapering-off period. Efficacy was primarily evaluated using the 18-item Brief Psychiatric Rating Scale (BPRS). Assessments were performed at baseline, and at weeks 1, 2, 4, 8, and 12. Results Switching to blonanserin resulted in a significant decrease in the mean total score on the BPRS from baseline (56.8 ± 9.4) to week 12 (42.1 ± 13.8, p < 0.001). The most common adverse events were extrapyramidal symptoms (n = 12, 23.1%), insomnia (n = 10, 19.2%), and emotional arousal (n = 6, 11.5%). Overweight or obese patients (body mass index ≥ 23 kg/m2, n = 33) who switched to blonanserin exhibited significant weight loss from 75.2 ± 9.3 kg at baseline to 73.5 ± 9.2 kg at week 12 (p = 0.006). The total cholesterol (baseline, 236.1 ± 47.6 mg/dl; endpoint [week 12], 209.9 ± 28.0 mg/dl; p = 0.005) and prolactin levels (baseline, 80.0 ± 85.2 ng/ml; endpoint [week 12], 63.2 ± 88.9 ng/ml; p = 0.003) were also significantly improved in patients with hypercholesterolemia or hyperprolactinemia. Conclusion The results of the present study suggest that switching to blonanserin may be an effective strategy for schizophrenic patients unresponsive to other antipsychotic treatments.
Collapse
Affiliation(s)
- Young Sup Woo
- Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Bo-Hyun Yoon
- Department of Psychiatry, Naju National Hospital, Naju, Korea
| | - Bong-Hee Jeon
- Department of Psychiatry, Naju National Hospital, Naju, Korea
| | - Jeong Seok Seo
- Department of Psychiatry, School of Medicine, Konkuk University, Chungju, Korea
| | - Beomwoo Nam
- Department of Psychiatry, School of Medicine, Konkuk University, Chungju, Korea
| | - Sang-Yeol Lee
- Department of Psychiatry, Wonkwang University School of Medicine, Iksan, Korea
| | - Young-Myo Jae
- Department of Psychiatry, Bongseng Memorial Hospital, Busan, Korea
| | - Sae-Heon Jang
- Department of Psychiatry, Bongseng Memorial Hospital, Busan, Korea
| | - Hun Jeong Eun
- Department of Neuropsychiatry, Presbyterian Medical Center-Jesus Hospital, Jeonju, Korea
| | - Seung-Hee Won
- Department of Psychiatry, School of Medicine, Kyungpook National University, Daegu, Korea
| | - Kwanghun Lee
- Department of Psychiatry, College of Medicine, Dongguk University, Gyeongju, Korea
| | - Jonghun Lee
- Department of Psychiatry, School of Medicine, Catholic University of Daegu, Daegu, Korea
| | - Won-Myong Bahk
- Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
| |
Collapse
|